Blog
DEF Announces Travel Stipend for East Coast Biologic & Small Molecule Free CME Bootcamp
With planning well underway for next month's East Coast Biologic & Small Molecule Free CME Bootcamp, the Dermatology Education Foundation (DEF) has announced the availability of a travel stipend for all eligible health care providers who attend both days of the...
As Many as 7 in 10 Patients Report Significant Mental Health Impact from Eczema
As many as seven in 10 people with eczema report that the disease has had a negative impact on their mental health in the past year. About two-thirds of adults with eczema had anxiety scores that were "borderline abnormal" or "abnormal," and 46% had "borderline...
Tips for Nails on the Dermalorian™ Podcast
While some cases of nail disease can be fairly easy to diagnose, others can present a challenge. Atypical presentations and concomitant diseases are just a few of the potential impediments to accurate diagnosis and treatment. In this episode of the Dermalorian™...
FDA Accepts NDA for Journey’s Rosacea Candidate
The FDA has accepted the New Drug Application (NDA) from Journey Medical Corp. for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User...
DERM2024 Call for Posters
We are now accepting e-poster submissions for DERM2024! Poster submissions are being accepted for digital display during the Clinically Relevant and Practical Case-Based Dermatology NP and PA CME Education Experience™. Posters may be submitted for inclusion in daily...
Sulfites are Allergen of the Year for 2024
By Joe Gorelick, MSN, FNP-C How many patients do you see with contact dermatitis? Negative patch testing results can be so frustrating and perhaps this year’s Allergen of the Year—sulfites--could be the culprit. Sulfites, commonly used preservatives in consumer...
$3.2 Million NIH Grant Funds Comprehensive Melanoma Initiative
A $3.2 million grant from the NIH will support the creation of Melanoma Resistance Evolution Atlas (MREA). Ultimately, researchers hope to develop novel approaches to prevention and treatment of resistant melanomas. Led by Dr. Roger Lo, professor of medicine and...
Rhode Island Legislation Recognizes Crucial Role of NPs, PAs in Providing Patient Care
By Joe Gorelick, MSN, FNP-C A 25-bill legislative package from Rhode Island legislators aimed at improving health care access and affordability in the Ocean State relies heavily on expansion of the primary care workforce, particularly NPs and PAs. RI Senate Health...
Letybo from Hugel is the Newest Botulinum Toxin Approved in US
The FDA has approved a new botulinum toxin formulation for aesthetic use in the US. Letybo from Hugel America, Inc., a division of Hugel Inc., is approved to treat moderate-to-severe glabellar (frown) lines in adults. Letybo (letibotulinumtoxinA-wlbg) is expected to...
FDA Considers Four New Indications for Bimzelx from UCB
Bimzelx® (bimekizumab-bkzx) from UCB is now under FDA review for a total of four potential new indications. Supplemental biologics license applications (sBLA) were submitted in February for three spondyloarthritides indications: psoriatic arthritis (PsA),...